IL6 and neoplasm: A systematic analysis of IL-6 as a predictive biomarker in NSCLC patients also revealed that those with a low baseline concentration of IL-6 in serum specimens or tumor tissues could derive more benefit from immune checkpoint inhibitors (ICIs) (20).